Table 2.

Analysis of correlation between EASIX, CRP, and mEASIX and clinical outcomes.

	ORR	CRS	ICANS	ICANS G3-4	Tocilizumab requirement	Cumulative steroid dose	ROC curve analysis
EASIX	[OR; p]	[OR; p]	[OR; p]	[OR; p]	[OR; p] [OR; p]	[β; R2; p]	[AUC; p]
Pre-lymphodepletion	0.980; 0.747	1.166; 0.296	1.015; 0.790	1.135; 0.047	1.030; 0.622	14.22; 0.066; 0.019	0.571; 0.42
Infusion	0.939; 0.238	1.129; 0.299	1.066; 0.267	1.192; 0.008	1.071; 0.196	17.75; 0.132; 0.001	0.623; 0.161
C-reactive protein	[OR; p]	[OR; p]	[OR; p]	[OR; p]	[OR; p]	[β; R2; p]
Pre-lymphodepletion	0.878; 0.007	1.102; 0.256	1.081; 0.098	1.045; 0.342	1.114; 0.015	5.759; 0.022; 0.179	–
Infusion	0.915; 0.50	1.060; 0.402	1.093; 0.070	1.107; 0.031	1.122; 0.013	8.440; 0.046; 0.054
Modified EASIX	[OR; p]	[OR; p]	[OR; p]	[OR; p]	[OR; p]	[β; R2; p]	[AUC; p]
Pre-lymphodepletion	0.993; 0.184	1.100; 0.229	1.007; 0.306	1.007; 0.242	1.007; 0.205	1.043; 0.042; 0.066	–
Infusion	0.995; 0.155	1.056; 0.262	1.011; 0.119	1.008; 0.034	1.007; 0.086	0.847; 0.080; 0.010	0.716; 0.014
I-mEASIX, [OR; p]
High (≥4) vs. Low (<4) risk		2.025; 0.240	1.103; 0.825	4.086; 0.034	2.051; 0.145	1.002; 0.178	2.025; 0.240

EASIX = LDH * Creatinine/Thrombocytes; Modified EASIX = LDH * CRP/Thrombocytes.

β Beta coefficient & R-squared, rather than OR, reported for linear regression.

AUC area under the curve, CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, EASIX Endothelial Activation and Stress Index, OR odds ratio, ORR overall response rate, ROC receiver operating characteristic.

Bold values indicates statistically significant.